Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

60.38
-1.1050-1.80%
Volume:1.09M
Turnover:65.10M
Market Cap:8.50B
PE:-26.44
High:60.92
Open:60.54
Low:59.21
Close:61.48
52wk High:95.49
52wk Low:34.61
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.88
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:18.27
PE(LYR):-4,951.61

Loading ...

Arrowhead rises 23.4%

TIPRANKS
·
Jul 23

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co (OTSKY)

TIPRANKS
·
Jul 22

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 19.25% in Regular Trading, Core Pipeline Plozasiran Achieves Key Late-Stage Trial Endpoints

Market Focus
·
Jul 22

Arrowhead Pharmaceuticals Shares up 18.1% Premarket After Blood-fat Drug Meets Late-stage Trial Goals

THOMSON REUTERS
·
Jul 22

Arrowhead Rises After Blood-fat Drug Meets Late-stage Trial Goals

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 8.64% in Pre-Market Trading, Core Pipeline Plozasiran Delivers Strong Results Across Multiple Key Trials

Market Focus
·
Jul 22

Arrowhead Pharma Announces Press Release on Plozasiran Phase 3 Shasta-3 and Shasta-4 Topline Results

Reuters
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Shows Significant Reduction in Acute Pancreatitis Events, 100% in High-risk Patients

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Demonstrates Consistent Safety Profile with no New Safety Signals

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Achieves 79% and 81% Median Triglyceride Reduction in Shasta-3 and Shasta-4

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - to File Supplemental Nda for Plozasiran with U.S. FDA Before End of 2026

THOMSON REUTERS
·
Jul 22

Press Release: Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Dow Jones
·
Jul 21

Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?

Simply Wall St.
·
Jul 18

Arrowhead Pharmaceuticals is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 18

Arrowhead Pharmaceuticals : JP Morgan Raises Target Price to $95 from $88

THOMSON REUTERS
·
Jul 17

U.S. Research Roundup-ibm, MSCI, US Bancorp

Reuters
·
Jul 17

Stifel Initiates Arrowhead Pharmaceuticals at Buy With $98 Price Target

MT Newswires Live
·
Jul 14

Arrowhead Pharmaceuticals : Stifel Initiates Coverage with Buy Rating; Target Price $98

THOMSON REUTERS
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and BrightSpring Health Services, Inc. (BTSG)

TIPRANKS
·
Jul 14